GE Healthcare Technologies invests in fish for leukemia and lymphoma test
GE Healthcare today announced that Clarient Diagnostic Services, Inc., a business of GE Healthcare has made significant improvements to its fluorescence in situ hybridization technology to improve virtual analysis of the test results for a variety of diseases blood, including leukemia, lymphoma, myeloma and myelodysplastic syndrome.
GE Healthcare Invests in FISH Technologies for Leukemia and Lymphoma Testing
March 5th, 2014 Alex Powell